(Q54569810)

1 June 2018

title

The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin. (English)

1 reference

1 June 2018

author name string

Dawn E Telford

1

1 reference

1 June 2018

Brian G Sutherland

2

1 reference

1 June 2018

Jane Y Edwards

3

1 reference

1 June 2018

Joseph D Andrews

4

1 reference

1 June 2018

P Hugh R Barrett

5

1 reference

1 June 2018

Murray W Huff

6

1 reference

1 June 2018

publication date

27 November 2006

1 reference

1 June 2018

Journal of Lipid Research

published in

1 reference

1 June 2018

volume

48

1 reference

1 June 2018

issue

3

1 reference

1 June 2018

page(s)

699-708

1 reference

1 June 2018

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

cites work

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M600439-JLR200

Comparisons of metabolism of apolipoprotein B in normal subjects, obese patients, and patients with coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M600439-JLR200

Thematic review series: patient-oriented research. What we have learned about VLDL and LDL metabolism from human kinetics studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M600439-JLR200

REVIEW: Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M600439-JLR200

Sterol absorption by the small intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M600439-JLR200

Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M600439-JLR200

Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M600439-JLR200

The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M600439-JLR200

Inhibition of intestinal cholesterol absorption by ezetimibe in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M600439-JLR200

Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M600439-JLR200

The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M600439-JLR200

Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M600439-JLR200

NPC1L1: evolution from pharmacological target to physiological sterol transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M600439-JLR200

Delineation of molecular changes in intrahepatic cholesterol metabolism resulting from diminished cholesterol absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M600439-JLR200

Effect of ezetimibe on the in vivo kinetics of apoB-48 and apoB-100 in men with primary hypercholesterolemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M600439-JLR200

Rationale for targeting multiple lipid pathways for optimal cardiovascular risk reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M600439-JLR200

Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M600439-JLR200

A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with p

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M600439-JLR200

Inhibition of both the apical sodium-dependent bile acid transporter and HMG-CoA reductase markedly enhances the clearance of LDL apoB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M600439-JLR200

Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M600439-JLR200

A novel inhibitor of oxidosqualene:lanosterol cyclase inhibits very low-density lipoprotein apolipoprotein B100 (apoB100) production and enhances low-density lipoprotein apoB100 catabolism through marked reduction in hepatic cholesterol content

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M600439-JLR200

Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M600439-JLR200

Fatty acids differentially regulate hepatic cholesteryl ester formation and incorporation into lipoproteins in the liver of the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M600439-JLR200

Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese hyperinsulinemic hamsters

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M600439-JLR200

Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M600439-JLR200

Inhibition of the apical sodium-dependent bile acid transporter reduces LDL cholesterol and apoB by enhanced plasma clearance of LDL apoB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M600439-JLR200

NPC1L1 haplotype is associated with inter-individual variation in plasma low-density lipoprotein response to ezetimibe

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M600439-JLR200

Evidence for a Niemann-pick C (NPC) gene family: identification and characterization of NPC1L1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M600439-JLR200

Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M600439-JLR200

Cholesterol-regulated translocation of NPC1L1 to the cell surface facilitates free cholesterol uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.M600439-JLR200

10.1194/JLR.M600439-JLR200

21 January 2018

Identifiers

DOI

1 reference

1 June 2018

PubMed ID

17130282

1 reference

1 June 2018